Duopharma Biotech Bhd

Duopharma Biotech Bhd maintains a debt-to-equity ratio of 0.65 and a current ratio of 2.6, indicating a moderate level of leverage and strong short-term liquidity. The company holds MYR 175.53 million in cash and equivalents, but its long-term debt of MYR 493.62 million suggests a need for careful capital structure management. The liquidity risk is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt. The company's profitability is reflected in a return on equity (ROE) of 11.54% and a return on assets (ROA) of 6.03%. These figures are in line with the industry's preferred metrics for profitability and returns, suggesting that Duopharma Biotech Bhd is generating returns comparable to its peers. The gross profit margin of 39.0% (MYR 363.14 million gross profit on MYR 931.69 million revenue) indicates a healthy margin, but the operating margin of 14.36% (MYR 133.79 million operating income) suggests that operating expenses are a significant portion of revenue. Duopharma Biotech Bhd operates through three primary segments: Consumer Healthcare (CHC), Ethical Classic, and Ethical Specialty. The CHC segment is responsible for over-the-counter products, while the Ethical Classic and Ethical Specialty segments focus on prescription drugs and specialty treatments, respectively. The company's geographic exposure is primarily in the domestic and regional markets, with no specific revenue concentration disclosed in the input data. The company's growth trajectory is supported by a strong revenue base of MYR 931.69 million. While the input data does not provide specific outlook figures for the current or next fiscal year, the company's operating cash flow of MYR 106.83 million and free cash flow of MYR 66.13 million suggest a capacity for reinvestment and growth. The capital expenditure of MYR -33.18 million indicates a reduction in capital spending, which may be a strategic move to preserve cash or a reflection of asset optimization. The risk assessment for Duopharma Biotech Bhd indicates a low dilution risk, with no immediate pressure for share issuance. The company's liquidity risk is moderate, and the key flag of negative net cash after subtracting total debt suggests a need for careful monitoring of debt levels and cash flow management. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events and disclosures for Duopharma Biotech Bhd include analyst estimates with a mean price target of MYR 1.73 and a median price target of MYR 1.72. The mean recommendation is 1.83, with one strong-buy, five buy, and no hold ratings. These analyst estimates suggest a generally positive outlook for the company's stock.